![Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19 Phase III results for remdesivir expected within weeks](https://cdn.cancerletter.com/media/2020/04/25200917/coronavirus-web2_4x3.jpg)
![Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19 Phase III results for remdesivir expected within weeks](https://cdn.cancerletter.com/media/2020/04/25200917/coronavirus-web2_4x3.jpg)
Cover Story
COVID-19 & CancerFree
Experts in infectious diseases and investors on Wall Street are honing in on two potential treatments for COVID-19: interleukin inhibitors and remdesivir.
COVID-19 Updates
![COVID-19 Updates](https://cdn.cancerletter.com/media/2021/05/04080942/covid-doodle.jpg)
![COVID-19 Updates](https://cdn.cancerletter.com/media/2021/05/04080942/covid-doodle.jpg)
In Brief
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence